EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Scalability of Sartobind® Rapid A Membrane for High Productivity Monoclonal Antibody Capture

Sabrina Yang, Ryszard Braczkowski, Shih-Hsun Chen, Ricarda Busse, Yudhi Li, Louis Fabri, Innocent Berbelle Bekard

Membranes · 27.09.2023 · 13 (10) · 815

DOI: 10.3390/membranes13100815 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Membranes, online erschienen am 27.09.2023. Verfasst von Sabrina Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: CSL Innovation Pty Ltd., 655 Elizabeth Street, Melbourne, VIC 3000, Australia. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSL Innovation Pty Ltd., Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Improved upstream titres in therapeutic monoclonal antibody (mAb) production have shifted capacity constraints to the downstream process. The consideration of membrane-based chromatographic devices as a debottlenecking option is gaining increasing attention with the recent introduction of high-capacity bind and elute membranes. We have evaluated the performance and scalability of the Sartobind® Rapid A affinity membrane (1 mL) for high-productivity mAb capture. For scalability assessment, a 75 mL prototype device was used to process 100 L of clarified cell culture harvest (CH) on a novel multi-use rapid cycling chromatography system (MU-RCC). MabSelect™ PrismA (4.7 mL) was used as a benchmark comparator for Protein A (ProtA) resin studies. Results show that in addition to a productivity gain of >10×, process and product quality attributes were either improved or comparable to the benchmark. Concentrations of eluate pools were 7.5× less than that of the benchmark, with the comparatively higher bulk volume likely to cause handling challenges at process scale. The MU-RCC system is capable of membrane operation at pilot scale with comparable product quality profile to the 1 mL device. The Sartobind® Rapid A membrane is a scalable alternative to conventional ProtA resin chromatography for the isolation and purification of mAbs from harvested cell culture media.

Schlagwörter

Stichwörter der Autor:innen

bioprocessingmembrane chromatographymonoclonal antibodyprocess intensificationprotein Arapid cycling

Autor:innen und Institutionen

  • CSL Innovation Pty Ltd., 655 Elizabeth Street, Melbourne, VIC 3000, Australia.
  • Sartorius Stedim Biotech GmbH, August-Spindler-Strasse 11, 37079 Goettingen, Germany.
  • Sartorius Stedim Singapore Pte Ltd., 30 Pasir Panjang Rd., #06-31A/32, Singapore 117440, Singapore.

Förderung

  • CSL Innovation Pty Ltd., Australia

Zitieren

APA

Yang, S., Braczkowski, R., Chen, S. H., Busse, R., Li, Y., Fabri, L., & Bekard, I. B. (2023). Scalability of Sartobind® Rapid A Membrane for High Productivity Monoclonal Antibody Capture. Membranes, 13(10), 815. https://doi.org/10.3390/membranes13100815

Vancouver

Yang S, Braczkowski R, Chen SH, Busse R, Li Y, Fabri L, et al. Scalability of Sartobind® Rapid A Membrane for High Productivity Monoclonal Antibody Capture. Membranes. 2023;13(10):815. doi:10.3390/membranes13100815

BibTeX
@article{Yang2023,
  author = {Yang, Sabrina and Braczkowski, Ryszard and Chen, Shih-Hsun and Busse, Ricarda and Li, Yudhi and Fabri, Louis and Bekard, Innocent Berbelle},
  title = {Scalability of Sartobind® Rapid A Membrane for High Productivity Monoclonal Antibody Capture},
  journal = {Membranes},
  year = {2023},
  volume = {13},
  number = {10},
  pages = {815},
  doi = {10.3390/membranes13100815}
}
Kostenlos starten →